[14C]SHR7280
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Assisted Reproduction
Conditions
Assisted Reproduction
Trial Timeline
Jun 7, 2024 → Jul 6, 2024
NCT ID
NCT06408948About [14C]SHR7280
[14C]SHR7280 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Assisted Reproduction. The current trial status is completed. This product is registered under clinical trial identifier NCT06408948. Target conditions include Assisted Reproduction.
What happened to similar drugs?
0 of 2 similar drugs in Assisted Reproduction were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06408948 | Phase 1 | Completed |
Competing Products
4 competing products in Assisted Reproduction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR7280 tablets + SHR7280 dry suspension | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Remimazolam Tosilate + Propofol Injection. | Jiangsu Hengrui Medicine | Phase 2 | 35 |
| Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG) | Merck | Phase 3 | 40 |
| Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH | Merck | Phase 3 | 32 |